Organization | King Hamad University

King Hamad University Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Al Sayh Bahrain (2010)

Organization Overview

First Clinical Trial

2013

NCT01923909

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

KHUH, RCSI-Bahrain | King Hamad University Hospital | King Hamad University Hospital, Bahrain

Active Ingredients

Drugs in Phase 4 Trials (3)

levobupivacaine (chirocaine) (2 trials)

methylprednisolone (medrol) (2 trials)

platelet-rich plasma (2 trials)

Drugs in Phase 3 Trials (1)

insulin human (humulin) (1 trial)

Drugs in Other Trials (6)

fentanyl (Innovar) (1 trial)

midazolam (versed) (1 trial)

oxygen (1 trial)

raisin (1 trial)

remifentanil (ultiva) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Fasciitis (Phase 3)

Fasciitis, Plantar (Phase 3)

Osteoarthritis (Phase 4)

Osteoarthritis, Knee (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 6
# of Trial APIs: 10